References
- Fisher, R. I. (1994). Treatment of aggressive non-Hodgkin's lymphoma. Cancer, 74, 2657–2661.
- The International non-Hodgkin's Lymphoma Prognostic Factor Project (1994). A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med., 329, 987–994.
- Shipp, M. A., Neubert, D., Janicek, J. et al. (1995). High-dose CHOP as initial therapy for patients with poor prognosis aggressive non-Hodgkin's lymphoma. A dose finding study. J. Clin. Oncol., 13, 2916–2923.
- Avilés, A., Guzmán, R., Delgado, S. et al. (1996). Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improves the prognosis in aggressive malignant lymphoma. Am. J. Hematol., 52, 275–280.
- Schenkein, D. P., Dixon, P., De Forges, J. F. et al. (1995). Phase I/II study of cyclophosphamide, carboplatin and etoposide and autologous hematopoeitc stem cell transplantation with postransplant interferon alfa 2b for patients with lymphoma and Hodgkin's disease. J. Clin. Oncol., 13, 2423–2431.
- Vitolo, V., Cortellazo, S., Liberati, A. M. et al. (1997). Intensified and high-dose chemotherapy with granulocyte colonys stimulating factor and autologous stem cell transplantation support as first line therapy in high-risk diffuse large cell lymphoma. J. Clin. Oncol., 15, 491–498.
- Gianni, A. M., Bregni, M., Siena, S. et al. (1997). High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N. Engl. J. Med., 332, 1290–1297.
- Avilés, A., Díaz-Maqueo, J. C., Talavera, A. and Guzmán, R. (1992). Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Invest New Drugs, 10, 351–355.
- Avilés, A., Díaz-Maqueo, J. C., Rodriguez, L. et al. (1990). Group-risk classification of non-Hodgkin's lymphoma. Arch. Invest Med., 21, 11–16.
- Avilés, A., Delgado, S., Nambo, M. J. et al. (1994). Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma. Int. J. Radiat. Oncol. Biol. Phys., 30, 799–804.
- Kaplan, E. L. and Meier, P. (1958). Non parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457–481.
- Avilés, A., Nambo, M. J., Talavera, A. et al. (1995). CM-CSF instead of hematological support during high-dose chemotherapy for refractory lymphoma. Leuk Lymph., 17, 327–332.
- Haouin, C., Lepage, E., Gisselbrecht, C. et al. (1994). Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma in firsts remission. A study of 464 patients. J. Clin. Oncol., 14, 2543–2548.
- Avilés, A., Huerta, J., Zepeda, G. et al. (1991). The role of maintenance therapy in the treatment of large cell lymphoma. Acta Oncol., 30, 959–964.
- Figlin, R. A. (1989). Biotherapy in clinical practice. Sem. Hematol., 26, 15–24.
- Gilewski, T. A. and Richards, J. R. (1990). Biological response modifiers in non-Hodgkin's lymphoma. Sem. Oncol., 17, 74–87.
- Borden, E. L. (1994). Innovative treatment strategies for non-Hodkgin's lymphoma and multiple myeloma. Sem. Oncol., 21 (Suppl. 6), 14–22.
- Avilés, A., Duque, G., Talavera, A. and Guzman, R (1996). Interferon alfa 2b as maintenance therapy in low-grade malignant lymphoma improves the duration of remission and survival. Leuk. Lymph., 20, 495–499.
- Longo, D. L. (1991). Biological agents and approaches in the management of patients with lymphoma. Hematol. Oncol. Clin. A, 5, 1067–1087.